Development of a quantitative immunofluorescence assay for detection of Stenotrophomonas maltophilia antibodies in patients with cystic fibrosis P. Gonçalves.

Slides:

Advertisements

Similar presentations

Cheryl Cameron, Mark W. Lodes, William M. Gershan

Advertisements

Serum matrix metalloproteinases in adult CF patients: Relation to pulmonary exacerbation Martin Roderfeld, Timo Rath, Richard Schulz, Werner Seeger,

Reduced levels of active GLP-1 in patients with cystic fibrosis with and without diabetes mellitus Magnus Hillman, Leif Eriksson, Lena Mared, Karin Helgesson,

Serology as a diagnostic tool for predicting initialPseudomonas aeruginosa acquisition in childrenwith cystic fibrosis Cori Daines, Donald VanDeVanter,

P. Whitaker, N. Shaw, J. Gooi, C. Etherington, S. Conway, D. Peckham

Zachary M. Sellers, Lori McGlocklin, Andrea Brasch

GFR estimates using cystatin C are superior to serum creatinine in adult patients with cystic fibrosis Paul M. Beringer, Levita Hidayat, Anna Heed, Ling.

Early rise of anti-Pseudomonas antibodies and a mucoid phenotype of Pseudomonas aeruginosa are risk factors for development of chronic lung infection—A.

How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF? Sarah P. Cohen, David M. Orenstein

Katarine Egressy, Michaelene Jansen, Keith C. Meyer

Megan R. Nelson, Craig R. Adamski, Audrey Tluczek

Amoxicillin–clavulanic acid resistance in fecal Enterobacteriaceae from patients with cystic fibrosis and healthy siblings Gwen Duytschaever, Geert Huys,

Urinary incontinence in 9��16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group W.J. Browne, C.J. Wood, M.

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study Doug L. Forrester, Alan J. Knox,

Laura Viviani, Baroukh M. Assael, Eitan Kerem

A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: A single-center study Maret L. Maliniak, Arlene A.

Cirrhosis and other liver disease in cystic fibrosis

Katelyn Krivchenia, Don Hayes, Joseph D. Tobias, Dmitry Tumin

Non-invasive liver elastography (Fibroscan) for detection of cystic fibrosis-associated liver disease Peter Witters, Kris De Boeck, Lieven Dupont, Marijke.

Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study Christine Rønne.

D. Stevens, P.J. Oades, N. Armstrong, C.A. Williams

Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox

Improved isolation of Stenotrophomonas maltophilia from the sputa of patients with cystic fibrosis using a selective medium M. Denton, M.J. Hall, N.J.

Disposition index identifies defective beta-cell function in cystic fibrosis subjects with normal glucose tolerance L. Merjaneh, Q. He, Q. Long, L.S.

Comparison of real time diagnostic chemistries to detect Pseudomonas aeruginosa in respiratory samples from cystic fibrosis patients J.L. Fothergill,

Gerd Döring, Patrick Flume, Harry Heijerman, J. Stuart Elborn

Implementation of European standards of care for cystic fibrosis �� Control and treatment of infection J.S. Elborn, M. Hodson, C. Bertram Journal of.

Vitamin A and lung function in CF

A.H. Gifford Journal of Cystic Fibrosis

Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden Per Kristian Knudsen, Hanne.

Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009 Yolanda P. Lillquist,

Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis Sanja Stanojevic, Valerie Waters, Joseph L.

M. Al-Aloul, M. Jackson, G. Bell, M. Ledson, M. Walshaw

Antonia V. Bennett, Donald L. Patrick, James F. Lymp, Todd C

Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis D.W. Reid, R. Latham, I.L.

Valerie Waters, Eshetu G

E. Tschiedel, H. Grasemann, F. Ratjen Journal of Cystic Fibrosis

Colon Cancer in Cystic Fibrosis patients: Is this a growing problem?

Sally H. Pattison, Geraint B. Rogers, Martin Crockard, J

Stenotrophomonas maltophilia in cystic fibrosis: Improved detection by the use of selective agar and evaluation of antimicrobial resistance P. Goncalves-Vidigal,

Nasal polyposis in lung transplant recipients with cystic fibrosis

Inflammatory and immunological biomarkers are not related to survival in adults with Cystic Fibrosis K.L. Moffitt, S.L. Martin, A.M. Jones, A.K. Webb,

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis Geraint B. Rogers, Lucas R. Hoffman,

Nutritional decline in cystic fibrosis related diabetes: The effect of intensive nutritional intervention H. White, K. Pollard, C. Etherington, I. Clifton,

Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients Valerie Waters, Eshetu G. Atenafu, Annie.

Segregation of children with CF diagnosed via newborn screening and acquisition of Pseudomonas aeruginosa Karen O. McKay, Peter J. Cooper, Peter P. van.

Alina A. Ionescu, Lisette S. Nixon, Dennis J. Shale

Predictive values of antibodies against Pseudomonas aeruginosa in patients with cystic fibrosis one year after early eradication treatment Matthias Kappler,

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

A new method of sweat testing: the CF Quantum®sweat test

V. Thompson, N. Mayer-Hamblett, M. Kloster, D. Bilton, P.A. Flume

Serology as a diagnostic tool for predicting initialPseudomonas aeruginosa acquisition in childrenwith cystic fibrosis Cori Daines, Donald VanDeVanter,

H. White, A.M. Morton, S.P. Conway, D.G. Peckham

Soluble inflammation markers in nasal lavage from CF patients and healthy controls Natalie Beiersdorf, Matthias Schien, Julia Hentschel, Wolfgang Pfister,

J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer

Daniel J. Smith, Gregory J. Anderson, Scott C. Bell, David W. Reid

C. R. Hansen, T. Pressler, K. G. Nielsen, P. Ø. Jensen, T

D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher

CFTR modulators and pregnancy: Our work has only just begun

‘Peeling paint’ dermatitis as a presenting sign of cystic fibrosis

Beta-lactam allergy in adults with cystic fibrosis

Cheryl Cameron, Mark W. Lodes, William M. Gershan

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)—A cause for concern?

Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L

Improved early diagnosis of Pseudomonas aeruginosa by real-time PCR to prevent chronic colonisation in a paediatric cystic fibrosis population Elaine.

Segregation—the perspectives of young patients and their parents

R. D. Gray, M. Imrie, A. C. Boyd, D. Porteous, J. A. Innes, A. P

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience C.R.

Presentation transcript:

Development of a quantitative immunofluorescence assay for detection of Stenotrophomonas maltophilia antibodies in patients with cystic fibrosis P. Gonçalves Vidigal, D. Schmidt, F. Stehling, U. Mellies, E. Steinmann, J. Buer, P.-M. Rath, J. Steinmann Journal of Cystic Fibrosis Volume 12, Issue 6, Pages 651-654 (December 2013) DOI: 10.1016/j.jcf.2013.04.011 Copyright © 2013 European Cystic Fibrosis Society. Terms and Conditions

Fig. 1 A) Antibody levels of S. maltophilia (Sm) whole cell in serum samples from healthy subjects (healthy), CF patients with chronic (CF chronic Sm), intermittent (CF intermittent Sm), and never Sm without P. aeruginosa (CF never Sm/Pa). Antibody levels are reported as titres. P values<0.0005 by non-parametric test were considered significantly different. B) Comparison of antibody titre between CF “never Sm/Pa” and CF never Sm but chronic Pa. Antibody titres did not differed between the groups (P=0.1898). Journal of Cystic Fibrosis 2013 12, 651-654DOI: (10.1016/j.jcf.2013.04.011) Copyright © 2013 European Cystic Fibrosis Society. Terms and Conditions

Fig. 2 Receiver operating curve (ROC) for IFA detecting serum antibodies against Sm whole cell. ROC data (area=0.8815; std. error=0.052; P=0.0002) of CF patients never colonised S. maltophilia/P. aeruginosa (Sm/Pa) versus CF patients with chronic S. maltophilia (Sm). Journal of Cystic Fibrosis 2013 12, 651-654DOI: (10.1016/j.jcf.2013.04.011) Copyright © 2013 European Cystic Fibrosis Society. Terms and Conditions